Back to search

University of British Columbia

Investigation of the 2A peptide StopGo mechanism through the development of a high-throughput screen

Abstract

dc:description

Continued development of antiviral responses requires more than immunity-based solutions; developing high-throughput cell-based assays to identify small molecule inhibitors against viral translation mechanisms will be essential for antiviral development moving forward. StopGo translation is a unique non-canonical translational event induced by the specific amino acid sequence of the 2A peptide that results in the release of a nascent polypeptide chain and translation downstream without termination or reinitiation. StopGo translation is important for viral replication in several viruses. Despite ample use in biotechnology and current applications in therapeutics, StopGo translation is not entirely understood, and there are no known modulators of the activity. We have developed a novel yeast growth reporter platform to identify chemical inhibitors of StopGo translation. Screening a large chemical library (68,000 compounds) identified 463 validated candidates. Compounds were then screened over several concentrations, validating 102 candidates with a dose-dependent response. Candidates were then evaluated for their ability to inhibit a model virus Cricket Paralysis Virus (CrPV) infection and elicit changes to protein localization in a fluorescent protein subcellular localization reporter. One compound led to decreased viral protein expression. -1 Programmed Ribosomal Frameshifting (-1 PRF) is another non-canonical translation mechanism; -1 PRF is essential for SARS-CoV-2 infection as enzymes critical for replication, such as the RNA-dependent RNA polymerase, are encoded in the -1 frame. As -1 PRF is highly conserved between coronaviruses, it is a strong candidate to target for viral inhibition. We have adapted the yeast growth reporter platform that senses 2A peptide StopGo translation to evaluate compounds capable of inhibiting -1 PRF. Screening of an extensive chemical library (68,000 compounds) identified 519 compounds that may inhibit -1 PRF. Candidates were not validated on this system, however. The development of this high-throughput screening platform lays the foundation of an adaptable cell-based screen that can be rapidly modified to identify inhibitors against viral translation mechanisms. Identification of compounds that inhibit StopGo translation contributes to the tool-kit available for 2A therapeutics and applications in biotechnology and can reveal mechanistic details of StopGo translation.

Degree

thesis:*
Name thesis:degree_name
Master of Science - MSc
Level thesis:degree_level
master's
Discipline thesis:degree_discipline
Biochemistry and Molecular Biology
Grantor dc:publisher
University of British Columbia
Year dc:date
2023

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Osborne, Tessa
Contributors dc:contributor
  • Jan, Eric

Rights

dc:rights
Statement dc:rights
  • Attribution-NonCommercial-NoDerivatives 4.0 International
Language dc:language
eng

Identifiers

dc:identifier.*
Handle dc:identifier
http://hdl.handle.net/2429/86080

Chain of custody

source
Harvested from
University of British Columbia
Base URL
circle.library.ubc.ca/oai/request
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
related terms
citation

Osborne, Tessa. Investigation of the 2A peptide StopGo mechanism through the development of a high-throughput screen. master's thesis, University of British Columbia, 2023. http://hdl.handle.net/2429/86080